Emagine Solutions Technology Raises NSF and State Funding to Advance AI-Powered Maternal Health Platform 

Emagine Solutions Technology, a Tucson-based maternal health technology company building remote patient monitoring tools and AI-powered pregnancy care platforms, has raised early-stage funding to advance its digital health ecosystem focused on improving maternal outcomes across the United States. The company develops The Journey Pregnancy App, alongside integrated hardware and software solutions designed to support high-risk pregnancies through continuous monitoring, patient engagement, and clinical connectivity.

The company’s funding profile includes multiple rounds of non-dilutive and grant-based capital, reflecting strong public-sector and innovation-driven support for maternal health technologies. Among its key investors is the U.S. National Science Foundation, which awarded the company approximately $1 million through its Small Business Innovation Research (SBIR) program to further develop AI models and integrate its platform with major electronic health record systems used in U.S. healthcare infrastructure. The NSF funding supports Emagine’s efforts to strengthen predictive analytics and expand clinical interoperability for its pregnancy monitoring platform.

Additional support has come from Arizona Commerce Authority, which awarded Emagine a $250,000 grant through its WearTech Applied Research Center. This funding is aimed at accelerating applied research in wearable health technologies and supporting pilot studies that evaluate the effectiveness of remote monitoring tools in maternal care settings across Arizona.

The company has also received backing from Springboard Enterprises, a nonprofit organization that supports high-growth women-led companies. Springboard’s involvement reflects its broader mission of accelerating female-founded healthcare and technology ventures, particularly those addressing gaps in women’s health and maternal outcomes.

Founded by Courtney Williams and José Juárez, Emagine Solutions Technology was created in response to firsthand experiences with gaps in prenatal care access and maternal health risks. The company’s platform combines handheld ultrasound technology, AI-driven risk assessment tools, and mobile patient engagement software to help expectant mothers and clinicians monitor pregnancy health in real time.

A key component of Emagine’s ecosystem is The Journey Pregnancy App, which allows users to track symptoms, receive personalized insights, and access remote monitoring features designed to identify early warning signs of complications such as preeclampsia. The platform integrates wearable devices and home monitoring tools to provide continuous data streams that can be shared with healthcare providers.

Emagine’s technology has been deployed in clinical research studies and pilot programs aimed at improving maternal health access in underserved and rural communities. These initiatives are part of a broader effort to address the United States’ maternal mortality challenges and disparities in prenatal care outcomes, particularly among high-risk populations.

The funding secured from the NSF, Arizona Commerce Authority, and Springboard Enterprises is being used to expand product development, enhance AI-driven predictive models, and scale integration with hospital systems and electronic health record platforms. The company is also focused on improving interoperability and expanding its regulatory-compliant infrastructure to support broader clinical adoption.

As maternal health continues to gain attention from both public and private investors, Emagine Solutions Technology is positioning itself at the intersection of AI, wearable health technology, and remote patient monitoring. With continued funding support and expanding clinical validation efforts, the company is working to build a more connected and data-driven approach to pregnancy care that aims to improve outcomes for mothers and infants nationwide.